Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Mar:289:114047.
doi: 10.1016/j.jviromet.2020.114047. Epub 2020 Dec 15.

Comparative evaluation of six immunoassays for the detection of antibodies against SARS-CoV-2

Felipe Pérez-García  1 , Ramón Pérez-Tanoira  2 , María Esther Iglesias  3 , Juan Romanyk  4 , Teresa Arroyo  5 , Peña Gómez-Herruz  6 , Rosa González  7 , Sara Lapeña García  8 , Juan Cuadros-González  9
Affiliations
Comparative Study

Comparative evaluation of six immunoassays for the detection of antibodies against SARS-CoV-2

Felipe Pérez-García et al. J Virol Methods. 2021 Mar.

Abstract

Objectives: Serologic techniques can serve as a complement to diagnose SARS-CoV-2 infection. The objective of our study was to compare the diagnostic performance of six immunoassays to detect antibodies against SARS-CoV-2: three lateral flow immunoassays (LFAs), one ELISA and two chemiluminescence assays (CLIAs).

Methods: We evaluated three LFAs (Alltest, One Step and SeroFlash), one ELISA (Dia.Pro) and two CLIAs (Elecsys and COV2T). To assess the specificity, 60 pre-pandemic sera were used. To evaluate the sensitivity, we used 80 serum samples from patients with positive PCR for SARS-CoV-2. Agreement between techniques was evaluated using the kappa score (k).

Results: All immunoassays showed a specificity of 100 % except for SeroFlash (96.7 %). Overall sensitivity was 61.3 %, 73.8 %, 67.5 %, 85.9 %, 88.0 % and 92.0 % for Alltest, One Step, SeroFlash, Dia.Pro, Elecsys and COV2T, respectively. Sensitivity increased throughout the first two weeks from the onset of symptoms, reaching sensitivities over 85 % from 14 days for all LFAs, being One Step the most sensitive (97.6 %), followed by SeroFlash (95.1 %). Dia.Pro, Elecsys and COV2T showed sensitivities over 97 % from 14 days, being 100 % for COV2T. One Step showed the best agreement results among LFAs, showing excellent agreement with Dia.Pro (agreement = 94.2 %, k = 0.884), COV2T (99.1 %, k = 0.981) and Elecsys (97.3 %, k = 0.943). Dia.Pro, COV2T and Elecsys also showed excellent agreement between them.

Conclusions: One Step, Dia.Pro, Elecsys and COV2T obtained the best diagnostic performance results. All these techniques showed a specificity of 100 % and sensitivities over 97 % from 14 days after the onset of symptoms, as well as excellent levels of agreement.

Keywords: CLIA; COVID-19; ELISA; Immunoassay; Lateral flow immunoassay; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

References

    1. Chew K.L., Tan S.S., Saw S., Pajarillaga A., Zaine S., Khoo C., Wang W., Tambyah P., Jureen R., Sethi S.K. Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infection. Clin. Microbiol. Infect. 2020;26 doi: 10.1016/j.cmi.2020.05.036. 1256.e9-1256.e11. - DOI - PMC - PubMed
    1. Egger M., Bundschuh C., Wiesinger K., Gabriel C., Clodi M., Mueller T., Dieplinger B. Comparison of the Elecsys® Anti-SARS-CoV-2 immunoassay with the EDI™ enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma. Clin. Chim. Acta. 2020;509:18–21. doi: 10.1016/j.cca.2020.05.049. - DOI - PMC - PubMed
    1. Garcia-Basteiro A.L., Moncunill G., Tortajada M., Vidal M., Guinovart C., Jiménez A., Santano R., Sanz S., Méndez S., Llupià A., Aguilar R., Alonso S., Barrios D., Carolis C., Cisteró P., Chóliz E., Cruz A., Fochs S., Jairoce C., Hecht J., Lamoglia M., Martínez M.J., Mitchell R.A., Ortega N., Pey N., Puyol L., Ribes M., Rosell N., Sotomayor P., Torres S., Williams S., Barroso S., Vilella A., Muñoz J., Trilla A., Varela P., Mayor A., Dobaño C. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat. Commun. 2020;11 doi: 10.1038/s41467-020-17318-x. - DOI - PMC - PubMed
    1. Guo L., Ren L., Yang S., Xiao M., Chang D., Yang F., Dela Cruz C.S., Wang Y., Wu C., Xiao Y., Zhang L., Han L., Dang S., Xu Y., Yang Q.-W., Xu S.-Y., Zhu H.-D., Xu Y.-C., Jin Q., Sharma L., Wang L., Wang J. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) Clin. Infect. Dis. 2020;71:778–785. doi: 10.1093/cid/ciaa310. - DOI - PMC - PubMed
    1. Huang A.T., Garcia-Carreras B., Hitchings M.D.T., Yang B., Katzelnick L., Rattigan S.M., Borgert B., Moreno C., Solomon B.D., Rodriguez-Barraquer I., Lessler J., Salje H., Burke D.S., Wesolowski A., Cummings D.A.T. A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease. Nat. Commun. 2020 doi: 10.1101/2020.04.14.20065771. - DOI - PMC - PubMed

Publication types